Harmony Biosciences Holdings (HRMY) Gross Margin (2020 - 2026)
Harmony Biosciences Holdings (HRMY) posted Gross Margin of 79.33% for Q1 2026, up 10.37% sequentially from 71.88% in Q4 2025, and down 335.0% YoY from 33.76% in Q1 2025.
Harmony Biosciences Holdings (HRMY) Gross Margin (2020 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Gross Margin for 7 years, with the latest figure at 79.33% in Q1 2026.
- Quarterly Gross Margin fell 335.0% year-over-year to 79.33% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 76.55% (down 179.0% YoY) and the FY2025 annual result came in at 77.16%, down 90.0% from the prior year.
- Gross Margin grew to 79.33% in Q1 2026 per HRMY's latest filing, from 71.88% in the prior quarter.
- Over five years, Gross Margin peaked at 82.75% in Q1 2022 and troughed at 71.88% in Q4 2025.
- A 5-year average of 79.19% and a median of 80.41% in 2022 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2023 and 2025: Gross Margin plunged 467 bps in 2023, then soared 46 bps in 2025.
- Over 5 years, Gross Margin stood at 79.05% in 2022, then dropped by 6 bps to 74.38% in 2023, then decreased by 2 bps to 72.97% in 2024, then retreated by 1 bps to 71.88% in 2025, then rose by 10 bps to 79.33% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 79.33%, 71.88%, and 75.09% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 75.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.81% |
| Mar 31, 2026 | 79.33% |
| Dec 31, 2025 | 71.88% |
| Sep 30, 2025 | 75.09% |
| Jun 30, 2025 | 80.97% |
| Mar 31, 2025 | 82.68% |
| Dec 31, 2024 | 72.97% |
| Sep 30, 2024 | 77.01% |
| Jun 30, 2024 | 81.40% |
| Mar 31, 2024 | 82.22% |
| Dec 31, 2023 | 74.38% |
| Sep 30, 2023 | 79.85% |
| Jun 30, 2023 | 81.37% |
| Mar 31, 2023 | 82.56% |
| Dec 31, 2022 | 79.05% |
| Sep 30, 2022 | 80.41% |
| Jun 30, 2022 | 82.32% |
| Mar 31, 2022 | 82.75% |
| Dec 31, 2021 | 80.47% |
| Sep 30, 2021 | 81.91% |